$143.71
0[0.00%]
Last update: 4:00PM Get Real Time Here
Alnylam Pharmaceuticals
(NASDAQ:ALNY)Latest News for Alnylam Pharmaceuticals Stock (NASDAQ:ALNY)
Alnylam Pharmaceuticals Stock (NASDAQ: ALNY)
Categories: All
Friday, April 19, 2024
Tuesday, April 09, 2024
Monday, April 08, 2024
- Analysts Express Confidence in Alnylam's Hypertension Drug Despite Mixed Trial DataVandana Singh - Apr 8, 2024, 2:37PM
- Reported Sunday, Alnylam Presents Results From The KARDIA-2 Phase 2 Study Of Zilebesiran Added To Standard Of Care Antihypertensives In Patients With Inadequately Controlled HypertensionBenzinga Newsdesk - Apr 8, 2024, 2:56AM
Tuesday, April 02, 2024
Wednesday, March 27, 2024
Monday, March 18, 2024
Tuesday, March 05, 2024
- Roche/Alnylam Blood Pressure Drug Aces In Mid-Stage Trial, Analyst Says Zilebesiran As Promising Opportunity In Addressing Global Hypertension ChallengesVandana Singh - Mar 5, 2024, 2:38PM
- HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $395 Price TargetBenzinga Newsdesk - Mar 5, 2024, 12:05PM
- Alnylam And Roche Initiated KARDIA-3 Phase 2 Study Of Zilebesiran Used As An Add-on Therapy For High Cardiovascular Risk And Uncontrolled Hypertension Despite Treatment With Two To Four Standard Antihypertensive MedicationsBenzinga Newsdesk - Mar 5, 2024, 7:42AM
- Alnylam/Roche Report KARDIA-2 Topline Study Results, The Study Met The Primary Endpoint Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care AntihypertensivesBenzinga Newsdesk - Mar 5, 2024, 7:40AM
Thursday, February 29, 2024
Wednesday, February 28, 2024
Friday, February 23, 2024
Wednesday, February 21, 2024
Tuesday, February 20, 2024
Friday, February 16, 2024
- Goldman Sachs Downgrades Alnylam Pharmaceuticals: Here's What You Need To KnowBenzinga Insights - Feb 16, 2024, 12:00PM
- RBC Capital Reiterates Outperform on Alnylam Pharmaceuticals, Maintains $235 Price TargetBenzinga Newsdesk - Feb 16, 2024, 11:53AM
- Chardan Capital Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $225Benzinga Newsdesk - Feb 16, 2024, 8:14AM
Thursday, February 15, 2024
- Why Is Alnylam Pharmaceuticals Stock Trading Lower On Thursday?Vandana Singh - Feb 15, 2024, 3:29PM
- Needham Reiterates Buy on Alnylam Pharmaceuticals, Maintains $200 Price TargetBenzinga Newsdesk - Feb 15, 2024, 1:28PM
- Alnylam Earlier Announced Updates To The Statistical Analysis Plan For The HELIOS-B Phase 3 Study Of Vutrisiran; Will Include Updates To The Primary And Secondary Endpoint Structure; Topline Results Are Expected To Be Available In Late June Or Early JulyBenzinga Newsdesk - Feb 15, 2024, 12:09PM
- Alnylam Sees FY24 Combined Net Product Revenues For AMVUTTRA, ONPATTRO, GIVLAARI And OXLUMO $1.4B-$1.5BBenzinga Newsdesk - Feb 15, 2024, 12:06PM
- CORRECTION Alnylam Pharmaceuticals Q4 2023 Adj EPS $(0.77) Beats $(1.32) Estimate, Sales $439.72M Miss $442.90M EstimateBenzinga Newsdesk - Feb 15, 2024, 12:04PM
- Cantor Fitzgerald Reiterates Neutral on Alnylam Pharmaceuticals, Maintains $165 Price TargetBenzinga Newsdesk - Feb 15, 2024, 9:17AM
- Alnylam Pharmaceuticals shares are trading lower after the company reported mixed Q4 financial results.Benzinga Newsdesk - Feb 15, 2024, 8:57AM
- Wolfe Research Initiates Coverage On Alnylam Pharmaceuticals with Peer Perform RatingBenzinga Newsdesk - Feb 15, 2024, 6:56AM
- Earnings Scheduled For February 15, 2024Benzinga Insights - Feb 15, 2024, 5:17AM
Wednesday, February 14, 2024
Tuesday, February 13, 2024
Monday, February 12, 2024
Tuesday, February 06, 2024
Thursday, February 01, 2024
Monday, January 22, 2024
Thursday, January 18, 2024
Monday, January 08, 2024
Sunday, January 07, 2024
- Alnylam Achieved Full Year 2023 Preliminary Global Net Product Revenues Of $1.241B For ONPATTRO, AMVUTTRA, GIVLAARI, And OXLUMO; December 31, 2023, Co Had Preliminary Cash, Cash Equivalents, And Marketable Securities Of ~$2.4BBenzinga Newsdesk - Jan 7, 2024, 8:14PM
- Alnylam Announces Preliminary Q4 And FY23 Global Net Product Revenues And Provides Additional Updates; Q4 Net Product Revenues For ONPATTRO And AMVUTTRA ~$79M And $175M; Q4 Net Product Revenues For GIVLAARI And OXLUMO ~$59M And $33MBenzinga Newsdesk - Jan 7, 2024, 8:13PM